2023 NAB Show®: Kalray Unveils ngenea®2, A Major Evolution of Its Open Data Management Platform, and Demonstrates It With AWS and Seagate
13.4.2023 20:35:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris : ALKAL), today announced the release of ngenea®2, the new version of its open data management and orchestration platform for data-centric applications. Leveraging Kalray’s Data Processor Unit (DPU) acceleration cards and Kalray’s pixstor™ software-defined storage solution, ngenea®2 addresses the challenges faced by a growing number of companies across all industries to be able to process, store, and manage their data faster, more efficiently, and more securely, wherever the data is located and whatever application they use.
ngenea®2 will be demonstrated at NAB 2023 by pixitmedia, Kalray’s subsidiary specialized in storage and data management solutions for the Media & Entertainment industry, in the Amazon (AWS) Innovation Zone and in the booth of its technology partner Seagate.
NEW ADVANCED FEATURES BOOSTED BY KALRAY DPU TECHNOLOGY
An increasing number of companies face challenges in their abilities to store, access, process, and control their data easily and efficiently when working within domains such as HPC, life science, media, finance, and manufacturing, to name a few. ngenea® offers a unique solution to address these challenges. It automates data management to ensure simple and efficient access to data wherever it is needed, on premises or in the cloud, and allows developers and data analysts to run complex data-intensive workflows in an easy and cost-efficient way.
ngenea®2 introduces advanced features to further address these needs. ngenea®2 consolidates data and infrastructure management into a single point of orchestrated control, enabling developers and data scientists to launch new, globally accessible data-centric workflows in seconds, across multiple on-premises, public and private cloud endpoints simultaneously and securely through each phase of their development. ngenea®2 exposes easy-to-use interfaces (“APIs”) to allow integration of third-party storage and application solutions into the ngenea namespace, providing a unified view of and instant global access to real-time data for developers. Moreover, one major evolution of ngenea®2 is its ability to leverage Kalray’s DPUs. With Kalray’s DPUs, ngenea®2 has been designed to give developers the best performance through in-storage NVMe processing and to offer AI-assisted unprecedented levels of insight into unstructured content assets to facilitate data-centric workflows.
DISPLAYING THE LATEST TECHNOLOGIES AT THE MECCA OF BROADCASTING
NAB, held from April 15-19, 2023 in Las Vegas, is one of the largest gatherings of Media & Entertainment (M&E) professionals in the world, featuring the latest technologies, services, and products in the areas of broadcasting, streaming, production, post-production, content creation, and distribution.
At the show, Kalray, through its subsidiary pixitmedia, will demonstrate multiple use cases to highlight how ngenea®2 manages and orchestrates global M&E workflows in diverse environments that include products and services from various technology partners, including AWS and Seagate, but also Adobe, Autodesk, Avid, Blackmagic, and Projective.
DEMONSTRATING AN END-TO-END CLOUD WORKFLOW AT AWS INNOVATION ZONE
At its kiosk in the Amazon Web Services (AWS) Create Innovation Zone (North Hall N2562H), pixitmedia will display a mixed editorial environment in AWS, mirroring a solution that it has in production with a Media & Entertainment Distribution arm of a major motion picture studio.
The demonstration will showcase how Kalray’s pixstor™ and ngenea®2 bring new levels of coherence and efficiency to media production, while improving security, controlling costs, and boosting collaboration. This solution includes an Amazon Elastic Compute Cloud (EC2) workstation in a pixstor™ cloud, with Projective’s Strawberry providing project containerization of a shared storage environment, enabling Adobe, Avid, and Blackmagic DaVinci Resolve participation in the workflow – all using the same core assets.
DEMONSTRATING AUTOMATED MOVEMENT OF MEDIA WITH SEAGATE AND AUTODESK
Also, technology partner Seagate is hosting pixitmedia to display a joint hyperconverged solution with three high-end workstations running Autodesk Flame, Flame Assist, and Blackmagic DaVinci Resolve. The demonstrated solution provides high-performance finishing suites, leveraging high-speed, native access to media data on pixstor™, boosted by Kalray hardware DPU accelerator cards and with ngenea®2 automating the movement of media between a customer NAS, Avid NEXIS, and Tier0 storage.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric markets, from edge to cloud.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005705/en/
Contact information
INVESTOR CONTACTS
E
ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72
PRESS CONTACTS
S
ylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom